Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant

320 110 Merci

Study Confirms in vitro Efficacy / Safety of Bentrio(TM) for Delta Variant

  • Prophylactic treatment of human nasal mucosa with Bentrio™ was reported to significantly reduce the viral titer vs. controls over 4 days, reaching a maximum reduction of 99% with the wild-type SARS-CoV-2 variant and more than 83% with the Delta variant
  • Bentrio™ administered 24 hours after infection saw the viral titer decrease by approximately 12-folds, and 3-folds on Day 4
  • Bentrio™ recently showed positive in vitro test results also against the Omicron variant in separate study

HAMILTON, BERMUDA / ACCESSWIRE / April 11, 2022 / Altamira Therapeutics Ltd. (NASDAQ:CYTO) (“Altamira” or the “Company”), a company dedicated to developing therapeutics that address important unmet medical needs, today announced that the International Journal of Molecular Sciences (IJMS) published a peer-reviewed paper confirming the Company’s positive research findings regarding the in vitro efficacy and safety of its drug-free nasal spray, Bentrio™, against the SARS-CoV-2 Delta variant.

The subject study, conducted by Altamira, tested the safety and efficacy of Bentrio™ against the Delta variant on an in vitro 3D model of the primary human nasal airway epithelium. Safety was assessed in assays for tight junction integrity, cytotoxicity, and cilia beating frequency. The study authors concluded, “The results suggest that AM-301 is safe and significantly decelerates SARS-CoV-2 replication in cell culture inhibition assays of prophylaxis (pre-viral load application) and mitigation (post-viral load application). Its physical (non-pharmaceutical) mechanism of action, safety and efficacy, warrant additional investigations both in vitro and in vivo for safety and efficacy against a broad spectrum of airborne viruses and allergens.”

Separately, on March 11, the Company announced positive efficacy data from testing its Bentrio™ nasal spray in vitro against the Omicron variant of SARS-CoV-2.

“We are encouraged by the study reported by IJMS, which demonstrates that Bentrio produced substantial reduction in the viral titer from infection with SARS-CoV-2,” said Thomas Meyer, Altamira Therapeutics’ founder, Chairman, and CEO. “With our COVAMID clinical trial, which we initiated in March 2022, we are now testing Bentrio in patients suffering from acute COVID-19. Enrolment has been progressing swiftly so far, and we hope to complete the randomized controlled study during the third quarter.”

“Already in the marketplace in selected European and soon also the first Asian countries, Bentrio offers an affordable, drug-free means of protection against airborne viruses and allergens,” Mr. Meyer added. “We are actively continuing to expand Bentrio’s commercialization footprint — driven by our recently established OTC Consumer Health business unit.”

The IJMS article, “Drug-Free Nasal Spray as a Barrier against SARS-CoV-2 and Its Delta Variant: In Vitro Study of Safety and Efficacy in Human Nasal Airway Epithelia,” is available at

About International Journal of Molecular Sciences

International Journal of Molecular Sciences is an international, peer-reviewed, open access journal providing an advanced forum for biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry, and is published semimonthly online by MDPI (

About Bentrio

AM-301, marketed as Bentrio™, is a drug-free nasal spray for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio™ forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. For more info, visit:

Bentrio™ is being distributed in selected European countries and is expected to become available through distributors in further countries in Europe, Asia and MENA. In the US, Altamira submitted a 510(k) application of Bentrio™ in the treatment of allergic rhinitis, which is currently under review by the FDA.

About Altamira Therapeutics

Altamira Therapeutics (Nasdaq: CYTO) is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore™ / SemaPhore™ platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio™; commercial) or for the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen® and Sonsuvi®; Phase 3). Founded in 2003, it is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit:

Forward-looking Statements

This press release may contain statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics’ strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may”, “might”, “will”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “projects”, “potential”, “outlook” or “continue”, or the negative of these terms or other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval and timing of commercialization of Bentrio™ (AM-301), Altamira Therapeutics’ need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics’ product candidates, the clinical utility of Altamira Therapeutics’ product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics’ intellectual property position and Altamira Therapeutics’ financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics’ capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption “Risk Factors” in Altamira Therapeutics’ Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics’ other filings with the SEC, which are available free of charge on the Securities Exchange Commission’s website at: Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

[email protected]

SOURCE: Altamira Therapeutics